177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

被引：20
|
作者：
Thakur, Shilpa [1 ]
Daley, Brianna [1 ]
Millo, Corina [2 ]
Cochran, Craig [1 ]
Jacobson, Orit [3 ]
Lu, Huiyan [4 ]
Wang, Zhantong [5 ]
Kiesewetter, Dale [3 ]
Chen, Xiaoyuan [5 ]
Vasko, Vasyl [6 ]
Klubo-Gwiezdzinska, Joanna [1 ]
机构：
[1] NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Ctr Clin, Bethesda, MD 20892 USA
[3] Natl Inst Biomed Imaging & Bioengn, Mol Tracer & Imaging Core Facil, NIH, Bethesda, MD USA
[4] NIDDK, NIH, Bethesda, MD 20892 USA
[5] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD USA
[6] Uniformed Serv Univ Hlth Sci, Dept Pediat Endocrinol, Bethesda, MD 20814 USA
来源：
CLINICAL CANCER RESEARCH | 2021年 / 27卷 / 05期
关键词：
NEUROENDOCRINE TUMORS; RADIONUCLIDE THERAPY; RADIOACTIVE IODINE; CARCINOMA; TOMOGRAPHY; PET/CT; ANTAGONISTS; MANAGEMENT; BENEFITS; AGONIST;
D O I：
10.1158/1078-0432.CCR-20-3453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: The goal of this study was to analyze the role of somatostatin receptor type 2 (SSTR2) as a molecular target for the imaging and treatment of thyroid cancer through analysis of SSTR2 expression and its epigenetic modulation and testing tumor uptake of different radiolabeled SSTR2 analogues. Experimental Design: We analyzed SSTR2 expression by immunostaining of 92 thyroid cancer tissue samples and quantified standard uptake values (SUVmax) of SSTR2 analogue, Ga-68-DOTA-TATE, by PET/CT imaging in 25 patients with metastatic thyroid cancer. We utilized human thyroid cancer cell lines characterized by differential SSTR2 expression (TT, BCPAP, and FTC133) and rat pancreatic cell line (AR42J) with intrinsically high SSTR2 expression for functional in vitro studies. SSTR2-high (AR42J) and SSTR2-low (FTC133) xenograft mouse models were used to test the uptake of radiolabeled SSTR2 analogues and their therapeutic efficacy in vivo. Results: Thyroid cancer had a higher SSTR2 expression than normal thyroid. Hurthle cell thyroid cancer was characterized by the highest Ga-68-DOTA-TATE uptake [median SUVmax, 16.5 (7.9-29)] than other types of thyroid cancers. In vivo studies demonstrated that radiolabeled DOTA-EB-TATE is characterized by significantly higher tumor uptake than DOTA-TATE (P < 0.001) and DOTA-JR11 (P < 0.001). Treatment with Lu-177-DOTA-EB-TATE extended survival and reduced tumor size in a mouse model characterized by high somatostatin (SST) analogues uptake (SUVmax, 15.16 +/- 4.34), but had no effects in a model with low SST analogues uptake (SUVmax, 4.8 +/- 0.27). Conclusions: A novel SST analogue, Lu-177-DOTA-EB-TATE, has the potential to be translated from bench to bedside for the targeted therapy of patients characterized by high uptake of SST analogues in metastatic lesions.
引用
收藏
页码：1399 / 1409
页数：11
相关论文
共 50 条
  • [31] Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE in the treatment of malignant insulinoma: a case report of remarkable clinical and imaging response
    Barbosa, D.
    Duarte, H.
    Paula Santos, A.
    Ferro, J.
    Prospero, I.
    Silva, D.
    Gil-Santos, S.
    Calheiros, R.
    Fontao de Castro, S.
    Ferreira, G.
    Teixeira, P.
    Lucena Sampaio, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S219 - S219
  • [32] Treatment with 177Lu-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors.
    Kwekkeboom, DJ
    Kam, BL
    Bakker, WH
    Kooij, PP
    de Herder, WW
    Srinivasan, A
    Erion, JL
    Bugaj, JL
    Schmidt, MA
    de Jong, M
    Krenning, EP
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 34P - 34P
  • [33] Hormonal crises induced by receptor radionuclide therapy with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate
    de Keizer, B.
    Krenning, E. P.
    Kam, B. L. R.
    van Essen, M.
    de Herder, W. W.
    Feelders, R. A.
    van Aken, M. O.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S220 - S221
  • [34] 'Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan: the plausible explanations and its implications for high-dose therapy with radiolabeled somatostatin receptor analogs
    Basu, Sandip
    Abhyankar, Amit
    Kand, Purushottam
    Kumar, Rakesh
    Asopa, Ramesh
    Rajan, Mysore Govinda Ramakrishna
    Nayak, Uday
    Shimpi, Hemant
    Das, Tapas
    Venkatesh, Meera
    Chakrabarty, Sudipta
    Banerjee, Sharmila
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (07) : 654 - 658
  • [35] Relationship of tumor absorbed doses of 177Lu-DOTA-TATE treatment and uptake in pre-therapeutic Ga68 DOTA-TATE PET/CT imaging
    Demirci, E.
    Kabasakal, L.
    Yeyin, N.
    Ocak, M.
    Toklu, T.
    Selcuk, N.
    Kanmaz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S264 - S264
  • [36] Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors: Preliminary results
    Kwekkeboom, DJ
    Kam, BL
    Bakker, WH
    Kooij, R
    Srinivasan, A
    Erion, JL
    Bugaj, JL
    Schmidt, MA
    de Jong, M
    Krenning, EP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1027 - 1027
  • [37] The theranostic somatostatin receptor antagonist pair 68Ga-OPS202/177Lu-OPS201 is superior to the agonist pair 68Ga-DOTA-TATE/177Lu-DOTA-TATE: a preclinical and clinical phase I/II study.
    Nicolas, G. P.
    Mansi, R.
    Kaufmann, J.
    Bouterfa, H.
    Maecke, H. R.
    Wild, D.
    Fani, M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 14 - 14
  • [38] Incidence of raised HbA1c and correlation with Somatostatin analogue therapy (SSA) in patients with Neuroendocrine Tumours (NET) receiving peptide receptor [177Lu]Lu-DOTA-TATE radionuclide therapy (PRRT)
    Eftychiou, N.
    Ilyas, H.
    Ahmed, H.
    Hassan, F.
    Eccles, A.
    Lewington, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S469 - S470
  • [39] Toxicity of Peptide Receptor Radiotherapy (PRRT) Using the Somatostatin Analogue DOTA-NOC Labelled with Y-90 or Lu-177
    Junak, D. Handkiewicz
    Baum, R. P.
    Jarzak, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
  • [40] Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma
    Minczeles, Noemie S.
    Bos, Eelke M. M.
    de Leeuw, Reinoud C. C.
    Kros, Johan M. M.
    Konijnenberg, Mark W. W.
    Bromberg, Jacoline E. C.
    de Herder, Wouter W. W.
    Dirven, Clemens M. F.
    Hofland, Johannes
    Brabander, Tessa
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (04) : 1195 - 1204
12345